Physician profile
Jerry L Hedrick
NPI 1164457412
$7,316.99
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,883 · 2020: $975 · 2021: $1,167 · 2022: $1,462 · 2023: $1,125 · 2024: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,822 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.94 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,076.45 | 2019-2024 | |
| Janssen Biotech, INC. | $769.04 | 2019-2024 | Tremfya |
| Pfizer INC. | $551.62 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $480.12 | 2019-2022 | |
| Genzyme Corporation | $419.29 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $344.80 | 2019-2023 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $298.30 | 2019-2024 | |
| Leo Pharma INC. | $252.23 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $241.68 | 2019-2024 | Odomzo |
| Vyne Pharmaceuticals INC. | $230.86 | 2020 | |
| Dermavant Sciences, INC. | $217.16 | 2022-2023 | Vtama |
| Amgen INC. | $214.81 | 2020-2024 | Otezla |
| Lilly USA, LLC | $206.36 | 2019-2023 | Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $158.66 | 2019-2021 | |
| Incyte Corporation | $155.25 | 2021-2023 | Opzelura |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $91.10 | 2019-2021 | |
| Ucb, INC. | $90.85 | 2022-2024 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $68.52 | 2022-2024 | Valchlor |
| Galderma Laboratories, L.P. | $53.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.43 | 2022-2023 | Spevigo |
| Genentech USA, INC. | $38.10 | 2019-2020 | |
| Neuronetics, INC. | $37.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.97 | 2023 | Sotyktu |
| Dusa Pharmaceuticals, INC. | $32.02 | 2019 | |
| Celgene Corporation | $30.59 | 2019 | |
| Sebela Pharmaceuticals INC. | $27.59 | 2019-2022 | |
| Organogenesis INC. | $26.67 | 2023 | Puraply |
| Mayne Pharma Commercial LLC | $24.08 | 2022 | |
| Merz North America, INC. | $23.89 | 2024 | |
| Dermira, INC. | $22.85 | 2020 | |
| Sensus Healthcare, INC. | $21.09 | 2021 | |
| Encore Dermatology INC. | $14.87 | 2019 | |
| Almirall LLC | $12.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Hedrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.